R Tuuminen1, S Loukovaara2. 1. Department of Ophthalmology, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland. 2. Unit of Vitreoretinal Surgery, Department of Ophthalmology, Helsinki University Central Hospital, Helsinki, Finland.
Abstract
PURPOSE: Vascular endothelial growth factor is a leading target to reduce macular oedema and improve visual acuity in patients with retinal vein occlusion (RVO), whereas the role of vascular destabilizing and fibroproliferative transforming growth factor (TGF)-β1 and matrix metalloproteinases (MMP)-2 and -9 in pathological manifestations of RVO is anticipated but less studied. METHODS: Undiluted vitreous samples were collected from three central RVO and one branch RVO eyes, all with neovascularization and fibrosis-related sight-threatening complications of RVO. Undiluted vitreous samples of 40 eyes operated due to non-ischemic condition either macular hole or pucker were used as controls. Growth factor and protease concentrations were measured by ELISA and gelatin zymography. RESULTS: Vitreous concentrations of TGF-β1 (92.0 ± 17.4 pg/ml vs 18.3 ± 27.0 pg/ml, mean ± SD; P=0.002) and MMP-9 (847.9 ± 1196.4 AU/ml vs 87.7 ± 174.0 AU/ml; P=0.010) were higher in the eyes with ischemic RVO than in the controls. CONCLUSIONS: High intravitreal levels of TGF-β1 and MMP-9 are found in RVO eyes having neovascular and fibrosis manifestation. Further studies are warranted to elucidate whether targeting TGF-β1 and MMP-9 could be beneficial in patients with ischemic RVO.
PURPOSE:Vascular endothelial growth factor is a leading target to reduce macular oedema and improve visual acuity in patients with retinal vein occlusion (RVO), whereas the role of vascular destabilizing and fibroproliferative transforming growth factor (TGF)-β1 and matrix metalloproteinases (MMP)-2 and -9 in pathological manifestations of RVO is anticipated but less studied. METHODS: Undiluted vitreous samples were collected from three central RVO and one branch RVO eyes, all with neovascularization and fibrosis-related sight-threatening complications of RVO. Undiluted vitreous samples of 40 eyes operated due to non-ischemic condition either macular hole or pucker were used as controls. Growth factor and protease concentrations were measured by ELISA and gelatin zymography. RESULTS: Vitreous concentrations of TGF-β1 (92.0 ± 17.4 pg/ml vs 18.3 ± 27.0 pg/ml, mean ± SD; P=0.002) and MMP-9 (847.9 ± 1196.4 AU/ml vs 87.7 ± 174.0 AU/ml; P=0.010) were higher in the eyes with ischemic RVO than in the controls. CONCLUSIONS: High intravitreal levels of TGF-β1 and MMP-9 are found in RVO eyes having neovascular and fibrosis manifestation. Further studies are warranted to elucidate whether targeting TGF-β1 and MMP-9 could be beneficial in patients with ischemic RVO.
Authors: M Iurlaro; G Loverro; A Vacca; G Cormio; D Ribatti; M Minischetti; R Ria; M Bruno; L Selvaggi Journal: Eur J Clin Invest Date: 1999-09 Impact factor: 4.686
Authors: T B Connor; A B Roberts; M B Sporn; D Danielpour; L L Dart; R G Michels; S de Bustros; C Enger; H Kato; M Lansing Journal: J Clin Invest Date: 1989-05 Impact factor: 14.808
Authors: Rishika Chaudhary; Robert A H Scott; Graham Wallace; Martin Berry; Ann Logan; Richard J Blanch Journal: Transl Vis Sci Technol Date: 2020-02-21 Impact factor: 3.283